A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

开始日期2024-11-15

申办/合作机构

Endeavor BioMedicines, Inc初创企业

NCT05817240

/ Completed临床1期

A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

开始日期2023-05-03

申办/合作机构

Endeavor BioMedicines, Inc初创企业

NCT04968574

/ Completed临床2期

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

开始日期2021-08-26

申办/合作机构

Endeavor BioMedicines, Inc初创企业

100 项与 Taladegib 相关的临床结果

登录后查看更多信息

100 项与 Taladegib 相关的转化医学

登录后查看更多信息

100 项与 Taladegib 相关的专利（医药）

登录后查看更多信息

项与 Taladegib 相关的文献（医药）

2024-10-01·ARCHIV DER PHARMAZIE

A novel indole derivative, 2‐{3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1H‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth

Article

作者: Kim, Minkyoung ; Ko, Hyuk Wan ; Jeon, Jiyeon ; Lee, Yoon Ji ; Lee, Kyeong ; Lee, Hankyu ; Jung, Joo Hyun ; Nada, Hossam ; Lee, Hwayoung ; Bhattarai, Deepak

Abstract:

The Hedgehog (Hh) signaling pathway plays important roles in various physiological functions. Several malignancies, such as basal cell carcinoma (BCC) and medulloblastoma (MB), have been linked to the aberrant activation of Hh signaling. Although therapeutic drugs have been developed to inhibit Hh pathway‐dependent cancer growth, drug resistance remains a major obstacle in cancer treatment. Here, we show that the newly identified, 2‐{3‐[1‐(benzylsulfonyl)‐1,2,3,6‐tetrahydropyridin‐4‐yl]‐2‐methyl‐1H‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone analog (LKD1214) exhibits comparable potency to vismodegib in suppressing the Hh pathway activation. LKD1214 represses Smoothened (SMO) activity by blocking its ciliary translocation. Interestingly, we also identified that it has a distinctive binding interface with SMO compared with other SMO‐regulating chemicals. Notably, it maintains an inhibitory activity against the SmoD477H mutant, as observed in a patient with vismodegib‐resistant BCC. Furthermore, LKD1214 inhibits tumor growth in the mouse model of MB. Collectively, these findings suggest that LKD1214 has the therapeutic potential to overcome drug‐resistance in Hh‐dependent cancers.

2023-12-01·Cold Spring Harbor molecular case studies

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons

Article

作者: Fillmore, Nathanael R ; La, Jennifer ; Hernandez, Kyle M ; Sung, Feng-Chi ; Metoki-Shlubsky, Noah ; Liu, Qiong ; Bihn, John R ; Grossman, Robert L ; Prokhorenkov, Andrew ; Brophy, Mary T ; Venkat, Aarti ; Paller, Channing J ; Elbers, Danne C ; Do, Nhan V

Veterans are at an increased risk for prostate cancer, a disease with extraordinary clinical and molecular heterogeneity, compared with the general population. However, little is known about the underlying molecular heterogeneity within the veteran population and its impact on patient management and treatment. Using clinical and targeted tumor sequencing data from the National Veterans Affairs health system, we conducted a retrospective cohort study on 45 patients with advanced prostate cancer in the Veterans Precision Oncology Data Commons (VPODC), most of whom were metastatic castration-resistant. We characterized the mutational burden in this cohort and conducted unsupervised clustering analysis to stratify patients by molecular alterations. Veterans with prostate cancer exhibited a mutational landscape broadly similar to prior studies, includingKMT2AandNOTCH1mutations associated with neuroendocrine prostate cancer phenotype, previously reported to be enriched in veterans. We also identified several potential novel mutations inPTEN,MSH6,VHL,SMO, andABL1. Hierarchical clustering analysis revealed two subgroups containing therapeutically targetable molecular features with novel mutational signatures distinct from those reported in the Catalogue of Somatic Mutations in Cancer database. The clustering approach presented in this study can potentially be used to clinically stratify patients based on their distinct mutational profiles and identify actionable somatic mutations for precision oncology.

2022-11-24·Journal of biomolecular structure & dynamics

Deep-learning based repurposing of FDA-approved drugs againstCandida albicansdihydrofolate reductase and molecular dynamics study

Article

作者: Joshi, Tanuja ; Chandra, Subhash ; Pundir, Hemlata

Candida albicans causes the fatal fungal bloodstream infection in humans called Candidiasis. Most of the Candida species are resistant to the antifungals used to treat them. Drug-resistant C. albicans poses very serious public health issues. To overcome this, the development of effective drugs with novel mechanism(s) of action is requisite. Drug repurposing is considered a viable alternative approach to overcome the above issue. In the present study, we have attempted to identify drugs that could target the essential enzyme, dihydrofolate reductase of C. albicans (CaDHFR) to find out potent and selective antifungal antifolates. FDA-approved-drug-library from the Selleck database containing 1930 drugs was screened against CaDHFR using deep-learning, molecular docking, X-score and similarity search methods. The screened compounds showing better binding with CaDHFR were subjected to molecular dynamics simulation (MDS). The results of post-MDS analysis like RMSD, RMSF, RG, SASA, the number of hydrogen bonds and PCA suggest that Paritaprevir, Lumacaftor and Rifampin can make good interaction with CaDHFR. Furthermore, analysis of binding free energy corroborated the stability of interactions as they had binding energy of -114.91 kJ mol^-1, -79.22 kJ mol^-1 and -78.52 kJ mol^-1 for Paritaprevir, Lumacaftor and Rifampin respectively as compared to the reference (-63.10 kJ mol^-1). From the results, we conclude that these drugs have great potential to inhibit CaDHFR and would add to the drug discovery against candidiasis, and hence these drugs for repurposing should be explored further.

项与 Taladegib 相关的新闻（医药）

2025-02-10

·药明康德

再达3期试验主要终点，突破性小分子疗法即将递交上市申请

▎药明康德内容团队编辑勃林格殷格翰（Boehringer Ingelheim）公司今天宣布，该公司的在研疗法nerandomilast，在3期临床试验FIBRONEER-ILD中达到主要终点，与安慰剂相比，在第52周时改善用力肺活量（FVC）与基线相比的绝对变化值。FVC是衡量肺功能的关键指标之一。基于这些结果，该公司计划向美国FDA和全球其它监管机构提交nerandomilast治疗渐进性肺纤维化（PPF）的新药申请。 Nerandomilast是一种偏向抑制磷酸二酯酶4B（PDE4B）的口服小分子抑制剂，具有抗炎症和抗纤维化的双重作用。该药物的临床开发计划包括两项3期研究——针对特发性肺纤维化（IPF）患者的FIBRONEER-IPF试验以及针对渐进性肺纤维化患者的FIBRONEER-ILD试验。2022年，它获得美国FDA授予的突破性疗法认定，用于治疗IPF。 PDE4是磷酸二酯酶（PDE）家族的一员，包含4个亚型（PDE4A-PDE4D），可通过特异性水解cAMP而调控促炎、抗炎细胞因子的产生。研究发现，抑制PDE4的活性可以使细胞内cAMP水平升高，激活蛋白激酶A（PKA），从而抑制NFκB和NFAT等信号通路而减少下游细胞因子和趋化因子的释放，因此以PDE4为靶点的疗法有望治疗多种炎症相关疾病。其中，PDE4B在控制钙诱导的钙释放（CICR）过程方面发挥作用，优先抑制PDE4B可维持治疗肺纤维化的疗效，同时避免某些不良事件。然而，PDE4的4种亚型的活性位点具有高度相似性，大多数PDE4抑制剂无法区分不同亚型。勃林格殷格翰的这款抑制剂在靶点选择性上有着显著优势——它对于PDE4B具有优先的抑制作用。初步数据显示，FIBRONEER系列试验在安全性和耐受性方面总体与2期特发性肺纤维化研究保持一致，总体不良事件与安慰剂组相当。 ▲Nerandomilast分子结构（图片来源：PubChem）去年9月，勃林格殷格翰宣布nerandomilast已经在治疗IPF的3期临床试验FIBRONEER-IPF中达到主要终点，显著改善IPF患者的肺功能。新闻稿指出，这是IPF领域十年来达到主要终点的首个3期临床试验。FIBRONEER-IPF和FIBRONEER-ILD的详细数据将在今年晚些时候公布。 IPF是最常见的进行性纤维化间质性肺病（ILD）之一。IPF的症状包括活动时呼吸困难、持续干咳、胸部不适、疲劳和虚弱，影响全球约300万人。该疾病主要影响50岁以上的患者，并影响男性患者多于女性。除了IPF之外，某些类型的ILD患者可能会出现称为进行性肺纤维化的表型。PPF的定义是患者出现呼吸道症状恶化，并带有疾病进展的生理和放射学特征。在治疗IPF和PPF领域，勃林格殷格翰之外，PureTech Health去年宣布，在研氘代小分子药物deupirfenidone在2b期临床试验中达到主要终点，显著减少患者FVC的下降幅度。百时美施贵宝（Bristol Myers Squibb）公司开发的口服溶血磷脂酸受体1（LPA1）拮抗剂BMS-986278，在PPF患者中进行的2期临床试验中也显著改善了患者的肺功能。此外，研发人员已经不满足于延缓患者肺功能下降的速度，转向开发逆转IPF疾病进程的药物。连续创业者John Hood博士去年在接受药明康德内容团队采访时表示，他联合创建的Endeavor Biomedicines公司的在研疗法ENV-101，在2a期临床试验中展现出逆转IPF疾病进程的能力。John Hood博士说：“这是以前从未观察到的进展。我们相信这不但是针对IPF的重要进展，也有潜力为其它致命纤维化疾病带来突破。” ▲Endeavor Biomedicines的首席执行官John Hood博士（图片来源：药明康德内容团队）相关阅读：超1亿美元助力！逆转疾病进程，创新疗法如何让人们活得更久、更好 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial. Retrieved February 10, 2025, from https://www.fiercebiotech.com/biotech/boehringer-widens-fibrosis-drugs-potential-use-after-boosting-lung-function-2nd-phase-3 [2] Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis. Retrieved February 10, 2025, from https://www.globenewswire.com/news-release/2025/02/10/3023409/0/en/Boehringer-s-nerandomilast-meets-primary-endpoint-in-Phase-III-study-FIBRONEER-ILD-in-progressive-pulmonary-fibrosis.html [3] Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Retrieved February 10, 2025, from https://www.globenewswire.com/news-release/2024/09/16/2946446/0/en/Boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-III-FIBRONEER-IPF-study.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法临床3期临床结果

2024-11-20

·Business Wire

First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis

SAN DIEGO--( BUSINESS WIRE )--Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that the first patient has been dosed in the Phase 2b WHISTLE-PF trial evaluating the safety and efficacy of ENV-101 (taladegib), the company’s lead investigational medicine, in individuals with idiopathic pulmonary fibrosis (IPF). ENV-101 is a novel Hedgehog signaling pathway inhibitor that demonstrated potential in a Phase 2a trial to be the first disease-modifying treatment for IPF. “ Initiating the WHISTLE-PF trial is an important milestone for our company as we continue to develop ENV-101 for the treatment of IPF, a relentless disease that has a worse prognosis than most cancers," said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines. “ Following the positive results from our Phase 2a trial of ENV-101, Endeavor BioMedicines is now intensely focused on efficiently advancing the WHISTLE-PF trial to get this potentially transformative drug to patients as quickly as possible.” IPF is a chronic, progressive lung disease with limited treatment options that affects approximately 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. Current standard-of-care therapies do not address the underlying cause of IPF. They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients. ENV-101 is designed to block a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases such as IPF and drives the continuous pathophysiologic buildup of scar tissue in the lungs. Results from the randomized, double-blind, placebo-controlled Phase 2a trial of ENV-101 showed that patients who received the investigational therapy experienced statistically significant improvements in lung function and total lung capacity, and reversal of multiple key quantitative measures of lung fibrosis through 12 weeks of treatment. There were no treatment-related serious adverse events, treatment-related grade 3 or 4 adverse events, or clinically meaningful safety findings on laboratory analyses, vital signs, electrocardiograms, or physical examination reported for ENV-101-treated patients. The Phase 2b WHISTLE-PF ( W ound-remodeling H edgehog-Inhibitor I LD S tudy T esting L ung F unction E ndpoints- PF ) clinical trial is a global, randomized, placebo-controlled study evaluating the therapeutic potential of ENV-101 in individuals with IPF ( NCT06422884 ). Endeavor BioMedicines intends to conduct the trial in 14 countries globally, including Australia, where the first patient was dosed. The WHISTLE-PF trial will evaluate the efficacy of a range of ENV-101 doses through 24 weeks of treatment, characterize the investigational compound’s safety, assess its effect on patient reported outcomes and its effects on lung capacity and lung fibrosis as measured by chest high-resolution computed tomography (HRCT). About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company’s second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X .

临床2期临床结果抗体药物偶联物

2024-09-13

·药明康德

超1亿美元助力！逆转疾病进程，创新疗法如何让人们活得更久、更好

如今，全球年龄超过60岁的人口已超过10亿，并将在2050年占据全球人口的近四分之一。随着全球老龄化进程的不断加速，“健康老龄化”也成了全世界各个国家共同关注的焦点之一。9月恰逢健康老龄月（Healthy Aging Month），药明康德内容团队将在本月发表与全球新锐公司领导者和老龄问题专家的一系列对话，从科学、医学、公共卫生等不同角度，向读者们呈现意见领袖的思考。在今天的这篇访谈中，Endeavor Biomedicines公司的首席执行官John Hood博士将介绍该公司治疗特发性肺纤维化（IPF）和癌症的创新疗法。这两种疾病对老年人群的影响尤其显著。该公司的在研疗法ENV-101是首个在临床试验中展现逆转IPF疾病进程能力的药物。近日Endeavor完成了1.32亿美元的C轮融资，旨在加快ENV-101和公司管线中另一款抗体偶联药物（ADC）的临床开发。通过针对疾病背后的生物学机制，Endeavor的创新疗法有望在延长患者生命的同时，改善他们的生活质量。药明康德内容团队：您好！恭喜贵公司完成1.32亿美元的C轮融资。Endeavor专注于IPF和癌症，您可以和读者分享一下为什么这两类疾病与健康老龄化的主题紧密相连？ John Hood博士：多谢邀请。如你所说，我们刚完成由顶尖投资人支持的1.32亿美元C轮融资，获得的资金将帮助推进我们在IPF和癌症方面的研发管线。IPF主要影响50到70岁的个体，它的疾病进展受到年龄相关变化的影响，比如端粒缩短和细胞衰老（senescence）。这些变化会妨碍肺组织的修复。与之类似，由于基因突变的积累和免疫监测系统的衰退，患上癌症的风险也随着年龄增长而升高。我们正在开发针对这些疾病根源的创新疗法，我们对这些药物解决显著健康挑战的潜力感到非常兴奋。药明康德内容团队：贵公司的主打研发项目ENV-101是一款治疗IPF的药物，您可以分享一下它的作用机制和前景么？ John Hood博士：ENV-101靶向Hedgehog信号通路。我们认为它具有改善肺功能和在IPF患者中逆转肺纤维化的潜力。近期，我们的2a期临床试验首次展现了它逆转IPF疾病进程的证据，而且在与肺功能和肺组织结构相关的多个临床终点中都观察到了疾病逆转的迹象。这是以前从未观察到的进展。我们相信这不但是针对IPF的重要进展，也有潜力为其它致命纤维化疾病带来突破。开发IPF疗法是我们首次涉足纤维化疾病，IPF是一种非常严重的疾病，患者的5年生存率甚至低于很多癌症类型。他们的治疗选择有限。现有的治疗选择只能有限地减缓肺纤维化的速度，但是它们都不能中止或逆转IPF的疾病进程。我们正在启动一项全球性的2b期临床试验，评估ENV-101治疗IPF的效果。Endeavor将专注于推动ENV-101的临床开发，尽快将这款疗法带给患者。药明康德内容团队：在ENV-101开发过程中您要面对哪些独特的挑战？ John Hood博士：IPF是一种罕见疾病，虽然在罕见病中它的患者人数相对较多，仅在美国就有大约15万患者，然而招募这些患者仍然非常困难。他们的身体状况通常很不好，患有多种合并症并且需要同时接受其它药物的治疗。在临床试验中需要剔除背景治疗或者合并症的影响，确定在研药物产生的疗效或引发的不良事件。达成这一目标需要克服多重挑战。药明康德内容团队：那贵公司如何解决这些临床试验方面的挑战？ John Hood博士：我们计划在全球至少6个国家和地区开展这项2b期临床试验。我们与临床合作伙伴和临床试验点紧密合作来完成患者的招募和治疗。我们公司内部有一个临床研究助理（CRAs）团队来专门支持临床试验点。每个试验点在任何时间都可以与我们的团队联系，讨论并且解决他们遇到的问题。我们正在构建这方面的能力，因为我相信对于临床试验点来说，能够直接与公司内部的团队联系，得到在患者招募和治疗方面的支持和引导非常关键。药明康德内容团队：开发一款新药需要全球合作伙伴的同心协力。 John Hood博士：是的，好的合作伙伴能够提供我们公司内部没有的能力和专长。Endeavor是家小公司。我们的员工大部分聚焦于临床开发。从头搭建和生产相关的基础设施的成本太高了。况且，在有药明康德这样的合作伙伴的情况下也没这个必要。在过去20年里，药明康德都是我值得信赖的合作伙伴。时间经常是最宝贵的资源。我确信药明康德能够按时、高质量地提供我们需要的服务。除此之外，我们还与临床合作伙伴密切合作，在其它国家和地区获得一线人员的支持，这非常重要。虽然我们尽力构建临床试验的能力，但是我们不可能在所有进行临床试验的国家设立办事处。药明康德内容团队：贵公司的另一款在研疗法ENV-501的适应症是癌症，您可以介绍一下这款疗法么？ John Hood博士：癌症可以说跟衰老息息相关。它由基因突变的积累驱动，而基因突变在老年群体中更为常见。Endeavor开发的ENV-501是一款新一代抗体偶联药物。我们聚焦于名为HER3的靶点，它在肿瘤中的表达比HER2更为常见。ADC这一治疗模式已经在临床实践中成功治疗多种癌症类型，但是它们仍然会产生显著的副作用。我们认为这是一个机会，在利用ADC的优效性同时限制它的脱靶毒性。ENV-501的设计旨在最小化在第一代ADC中观察到的脱靶毒性。我们认为这一策略可能让ENV-501具有更好的安全性和耐受性，从而让我们有机会治疗在老年人群中常见的癌症。药明康德内容团队：多谢您拨冗分享洞见和Endeavor公司令人兴奋的进展。贵公司治疗年龄相关疾病的创新策略令人鼓舞。 John Hood博士：谢谢你的邀请。为患者开发新药虽然非常具有挑战性，但当你看到开发出的新药能够延长患者的生命并改善他们生活时，又是非常令人欣慰的。开发针对这些疾病根源的创新药物并不容易，需要巨大的付出，需要真正想让患者活得更久，活得更好的人们的合作和持久的奉献。内容来源于网络，如有侵权，请联系删除。

抗体药物偶联物临床结果临床研究申请上市

100 项与 Taladegib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10671	-	-	DB12550

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
进行性纤维化间质性肺病	临床2期	美国	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	阿根廷	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	澳大利亚	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	奥地利	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	比利时	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	加拿大	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	法国	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	德国	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	爱尔兰	Endeavor BioMedicines, Inc初创企业	2024-11-15
进行性纤维化间质性肺病	临床2期	意大利	Endeavor BioMedicines, Inc初创企业	2024-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04968574 (ENV-IPF-101, ATS2024) 人工标引	临床2期	特发性肺纤维化	41	ENV-101	艱壓衊築膚醖簾築簾築(膚遞鹽網遞夢鹹夢衊壓) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. 鬱鬱餘簾鏇鑰淵蓋艱構 (範壓餘餘簾獵膚製顧襯 ) 更多	积极	2024-05-19
ENV-101 (EADV2023)	临床2期	基底细胞癌 PTCH1 Loss of Function mutations	44	Taladegib 200 mg	簾簾簾憲構範襯願鹽壓(齋蓋夢艱遞構廠蓋艱廠) = Patient reported alopecia during the study 糧鏇積鹽蓋夢積鹹襯願 (憲鑰鏇憲遞鬱積鹹製鏇 ) 更多	积极	2023-10-11
ENV-101 (EADV2023)	临床2期	基底细胞癌 PTCH1 Loss of Function mutations	44	Vismodegib		积极	2023-10-11
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	临床1期	转移性实体瘤	63	Crenigacestat + Taladegib	鬱醖繭築廠遞窪觸壓簾(製願膚願築淵觸選築糧) = 淵醖壓繭窪鬱遞鏇夢願廠艱膚夢觸顧觸鹹夢顧 (醖願襯鬱衊餘淵鏇醖選 )	不佳	2021-03-08
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	临床1期	转移性实体瘤	63	Crenigacestat + LY3023414	鬱醖繭築廠遞窪觸壓簾(製願膚願築淵觸選築糧) = 衊顧窪鹹廠襯繭選醖齋廠艱膚夢觸顧觸鹹夢顧 (醖願襯鬱衊餘淵鏇醖選 ) 更多	不佳	2021-03-08
NCT01919398 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	19	LY2940680 (Cohort 1: 100 mg LY2940680)	窪積壓窪夢範製鬱範壓 = 廠醖醖醖膚鏇鑰艱鹹積選壓壓選窪膚鏇夢網網 (夢窪獵製構襯艱網壓鏇, 艱膚網繭憲糧製艱夢簾 ~ 鑰獵構艱顧範鏇淵醖顧) 更多	-	2019-09-11
NCT01919398 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	19	LY2940680 (Cohort 2: 200 mg LY2940680)	窪積壓窪夢範製鬱範壓 = 鏇醖膚簾遞膚淵簾選衊選壓壓選窪膚鏇夢網網 (夢窪獵製構襯艱網壓鏇, 觸顧選遞選築夢艱簾鑰 ~ 餘糧願鏇鬱鬱餘廠餘選) 更多	-	2019-09-11
NCT01746745 (CTgov)	临床1期	-	6	[^14C]-LY2940680	齋鏇鏇簾憲觸築構齋觸(夢壓願糧淵餘壓窪鹽簾) = 顧築蓋糧憲醖鬱衊廠繭遞鏇醖選觸遞糧鬱壓餘 (窪積鏇醖鑰齋襯顧齋鏇, 2.81) 更多	-	2019-07-22
NCT01919398 (Pubmed \| Invest New Drugs) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	19	taladegib	構構鏇積齋積糧觸簾顧(襯廠襯襯構淵願壓鑰廠) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) 鏇選繭鹹觸醖糧廠醖膚 (鬱範簾醖遞遞簾積衊齋 ) 更多	积极	2018-08-01
NCT01226485 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	基底细胞癌 \| 晚期癌症	84	LY2940680	鬱艱製衊鏇選願鹽鬱蓋(夢鹽膚鹹鬱選積範糧簾) = 顧選獵鏇憲觸齋範顧夢憲鹹範獵築簾蓋築窪廠 (窪衊壓衊網繭夢築鬱餘 ) 更多	积极	2018-05-01